Skip to main content
Jacobio Pharmaceuticals Group Co., Ltd. logo

Jacobio Pharmaceuticals Group Co., Ltd. — Investor Relations & Filings

Ticker · 1167 HKEX Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2025-06-03 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 1167

About Jacobio Pharmaceuticals Group Co., Ltd.

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co., Ltd. is a biopharmaceutical company specializing in the in-house discovery and development of innovative oncology therapies. The company is committed to providing breakthrough treatment solutions for patients by focusing its research and development pipeline on six major tumor signaling pathways: KRAS, Tumor Immunity, Tumor Metabolism, P53, RB, and MYC. Jacobio utilizes advanced drug discovery platforms, including induced allosteric mechanisms, to develop novel and improved medicines. The company primarily focuses on developing new drugs at the clinical stage, with the strategic goal of positioning its core projects among the top three globally in their respective therapeutic areas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2025
Share Issue/Capital Change Classification · 1% confidence The document is a HKEX FF301 “Monthly Return for Equity Issuer… on Movements in Securities,” reporting authorized share capital and movements in issued and treasury shares. It is a regulatory disclosure of capital structure changes (even though no changes occurred this month). This falls under announcements of share issue/capital changes rather than an annual or interim report or earnings release. Hence it is classified as SHA (Share Issue/Capital Change).
2025-06-03 English
INSIDE INFORMATION - JACOBIO'S KRAS G12C INHIBITOR GLECIRASIB APPROVED FOR MARKET LAUNCH
Regulatory Filings Classification · 1% confidence The document is an ‘Inside Information’ announcement made under Rule 13.09 of the Hong Kong Listing Rules, disclosing regulatory approval of a drug and related milestone payment. It is not a financial report, earnings release, AGM material, or capital/financing notice, but rather a general regulatory announcement required by the exchange. This falls into the fallback category “Regulatory Filings.”
2025-05-22 English
FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is the “Form of Proxy for the 2025 Annual General Meeting,” which is a solicitation package sent to shareholders to provide information and request their voting instructions ahead of the AGM. It is not the actual AGM presentation or the vote results but is clearly aimed at proxy solicitation. Under the definitions, this falls squarely into the Proxy Solicitation & Information Statement category (PSI).
2025-05-14 English
NOTICE OF 2025 ANNUAL GENERAL MEETING
AGM Information Classification · 1% confidence The document is a formal notice convening the company’s Annual General Meeting, specifying meeting date, agenda items (ordinary and special resolutions), proxy details, and voting procedures. It is not the full annual report or financial statements themselves but the notice/agenda for the AGM. According to our taxonomy, this falls under AGM Information (Code: AGM-R).
2025-05-14 English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL G
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a shareholder circular containing detailed information on proposed resolutions for the Annual General Meeting (AGM) – including general mandates to issue and repurchase shares, re-election of directors, amendments to the memorandum and articles of association, and the notice of AGM with proxy instructions. It is not the full annual report or financial statements, nor merely an announcement of publication. This type of pre-meeting information and solicitation of shareholder votes is classified as a Proxy Solicitation & Information Statement.
2025-05-14 English
PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 1% confidence The document is an announcement under HKEX Listing Rule 13.51(1) concerning proposed amendments to the company’s constitutional documents (the Memorandum and Articles of Association) to align with regulatory and housekeeping changes, and it will be subject to shareholder approval at the upcoming AGM. This is a governance‐related notice about internal company rules. It does not present full financial results or a proxy solicitation document but rather pertains to governance structure changes. Therefore it best fits the “Governance Information” category (CGR).
2025-05-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.